French Health service Economies In 1993

31 July 1994

Lower rates of French health care reimbursement which took effect in August 1993 under France's Veil plan yielded economies of almost 2 billion french francs ($368.5 million) last year, says the national health fund, the CNAM.

The plan explains the slight slowdown in overall health care spending growth, which rose 5.7% last year compared to 7.1% in 1992, says data from the accounts commission. However, while the CNAM confirms a tendency for spending to slow down, this does not apply to the drug sector as a whole, where spending went up 7.5% last year against 7.4% in 1992.

It says 1993's savings include 859 million francs ($160.2 million) on medical fees, 1.1 billion francs on prescriptions and 30 million francs on other spending. This calculation takes account only of the 5% drop in reimbursement of drugs and medical fees, and not the rise in hospital day-rates, but shows that without the Veil measures, reimbursement outside the hospital sector would have risen 5% in 1993 instead of 4.1%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight